Connect to other sites within the UBM Medica Network
Nilotinib, Dasatinib Offer Similar Outcomes in CML Patients
A propensity score–matched comparison of two phase II trials found that dasatinib and nilotinib offer similar responses and outcomes as first-line therapy for patients with chronic-phase CML.
ABCB1 mRNA Could Predict TKI Response in CML
Early evaluation of ABCB1 mRNA expression may help identify CML patients who are likely to be resistant to first- and second-generation tyrosine kinase inhibitors.
Post-Transplant TKI Maintenance Yields Promising Results in High-Risk CML, ALL
Maintenance therapy with TKIs following allogeneic HSCT is feasible and may improve outcomes in patients with high-risk Philadelphia chromosome–positive leukemia.
Life Expectancy in CML Patients Approaching General Population’s
A study covering 4 decades of patients with chronic myeloid leukemia in Sweden found dramatic improvements in life expectancy since the advent of tyrosine kinase inhibitor therapy.
CML Patients on TKIs May Have Increased Risk of Thromboembolic Events
Patients with chronic myeloid leukemia who are treated with tyrosine kinase inhibitors could be at increased risk of long-term cardiovascular toxicity.
Early TKI Responses Predict CML Survival, Especially With Dasatinib
Two studies show that early deep responses with TKIs yield lasting positive outcomes in CML patients, and that dasatinib outperforms imatinib.
Five-Year Results Support First-Line Dasatinib Use in CML
A 5-year analysis of the DASISION trial showed that dasatinib continued to offer better responses than imatinib in patients with chronic myeloid leukemia.
By clicking Accept, you agree to become a member of the UBM Medica Community.